Studies on chemically modified forms of the myelin basic protein: Requirements for encephalitogenicity  by Wood, D.D. et al.
Volume 66, number 2 FEBS LETTERS July 1976 
STUDIES ON CHEMICALLY MODIF IED FORMS OF THE MYELIN BASIC PROTEIN:  
REQUIREMENTS FOR ENCEPHALITOGENIC ITY  
D. D. WOOD and M. A. MOSCARELLO 
Dept. of Biochemistry, Hospital for Sick Children, Toronto, Ontario, Canada 
and 
R. M. EPAND 
Dept. of Biochemistry, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada 
Received 10 May 1976 
1. Introduction 
The basic protein of myelin is one of the major 
protein constituents isolated from this membrane. 
This protein is responsible for the induction of 
experimental l ergic encephalomyelitis (EAE) in a 
variety of animals including the guinea pig. A 
nonapeptide (residues 114-122 inclusive) derived 
from this basic protein is encephalitogenic in the 
guinea pig [1]. It has been shown that substitution 
of amino acid residues 3, 8 or 9 in this nonapeptide 
destroys its encephalitogenic activity [2,3]. However, 
it has not been shown that this amino acid region 
in the intact protein is the sole requirement for 
encephalitogenic activity although chemical modifica- 
tion of the sole tryptophan residue 116 greatly lowers 
this activity [4]. 
The modified proteins were tested for their ability 
to induce EAE in the guinea pig. In the present work, 
we show that although this peptide sequence may be 
necessary, it is not a sufficient condition to determine 
encephalitogenic activity. 
In support of the view that the linear sequence 
Trp . . . .  Gin, Lys is not a sufficient condition for 
EAE activity, the results with gastric inhibitory poly- 
peptide (GIP) are pertinent. This sequence, rarely 
found in proteins has been demonstrated in GIP [5]. 
The lack of activity of GIP in the guinea pig has 
given the impetus to a study of other factors reported 
here. 
2. Materials and methods 
The basic protein was isolated from the myelin 
fraction of normal human white matter by the 
method of Lowden et al. [6]. A sample of the 
bovine basic protein (A1) was kindly provided by 
Dr E. H. Eylar (Playfair Neurosciences Unit, 
1 Spadina Crescent, Toronto) and the gastric 
inhibitory peptide [5] was a gift from Dr J, C. Brown 
(Dept. of Physiology, University of British Columbia). 
The synthetic encephalitogenic onapeptide was 
purchased from Beckman Inst. Co. 
The bovine basic protein was reacted with nitro- 
malonyl dialdehyde by the method of Signor et al. [7] 
as previously described for the human basic protein 
[8]. The resulting/5-(5-nitro-2-pyrimidyl) ornithine 
derivative of the basic protein (NP-A1) was reduced 
with sodium borohydride to the 1,4,5,6,-tetrahydro- 
pyrimidyl derivative (THP-A1) [7]. NP-A1 (10 mg) 
was suspended in 0.8 ml absolute thanol; 0.2 ml of 
0.1 N NaOH was added followed by 10 mg sodium 
borohydride which was added as a dry powder with 
stirring. Most of the yellow colour disappeared from 
the solution after a few minutes. After 10 min, the 
reaction was stopped by the addition of 2 ml of 
0.2 M acetic acid. The resulting turbid suspension was 
dialyzed against several changes of distilled water and 
the final product recovered by lyophilization. 
There are 10 histidine and 4 tyrosine residues in 
the basic protein of normal human myelin which can 
29 0 North-Holland Publishing Company - Amsterdam 
Volume 66, number 2 FEBS LETTERS July 1976 
react with iodine to form mono- or di-iodo derivatives. 
Ten mg of the basic protein from human myelin was 
suspended in 0.01 M sodium phosphate buffer, 
pH 9.25. A seven-fold molar excess of iodine (with 
respect to the basic protein) dissolved in 1 ml of 
chloroform was shaken with the suspension of basic 
protein. The iodine colour disappeared and the 
chloroform layer was removed and discarded. This 
procedure was repeated with the same amount of 
iodine. The protein was recovered as a precipitate at 
the chloroform-water interface, washed with acetone 
and dried under vacuum. Normal human basic protein 
was modified with citraconic anhydride according to 
the method of Gibbons et al. [9]. Ten mg of basic 
protein was suspended in 4.0 ml of 0.1 M (NH4)2CO3, 
pH 8.8. A 100-fold excess of citraconic anhydride 
(with respect to the basic protein) was dissolved in 
0.7 ml of (NH4)2CO3 and this was added to the basic 
protein solution. The reaction was carried out at 4°C. 
The pH was maintained at pH 8.8 by the addition of 
concentrated NH4OH until the reaction was complete. 
The solution was dialysed against distilled water which 
had been adjusted to pH 8.8 with NH4OH using 
Thomas tubing 3787-H45, with a molecular weight 
cut-off of 3500. 
For enzymatic hydrolysis, 150 tag of gastric 
inhibitory polypeptide was suspended in 500 tal of 
NH4CO3 containing 0.001 M Ca ++. The concentration 
of trypsin used was 1% of that of the protein con- 
centration. Hydrolysis was allowed to proceed for 
24 h at 37°C. The sample was lyophilized and then 
suspended in 200 tal of physiological saline combined 
with Freund's adjuvant and injected into guinea pigs. 
The intact and modified basic proteins were sus- 
pended in equal volumes of physiological saline and 
Freund's complete adjuvant to give a final concentra- 
tion of either 50 tag protein or 100 tag protein per 
100 tal. 100 tal of protein was injected intradermally 
into the nape of the neck of each guinea pig. 
3. Results and discussion 
It can be seen from table 1 that the intact basic 
protein from either bovine or human myelin was 
encephalitogenic in the guinea pig. The commercially 
available synthetic nonapeptide corresponding to
residues 114-122 of the intact bovine basic protein 
was considerably ess encephalitogenic than the 
intact protein. A number of laboratories have reported 
the nonapeptide tobe highly encephalitogenic [10,11] 
The important amino acids for the encephalitogenic 
activity of this nonapeptide in the guinea pig was 
Trp . . . .  Gin, Lys. The terminal Lys could be replaced 
Table 1 
The encephalitogenic activity of human and bovine myelin basic protein, gastric 
inhibitory polypeptide, and chemically modified human and bovine basic protein 
Protein 
Protein Number of guinea 
Amino ac id (s )  concentration pigs which developed 
~g per guinea clinical EAE 
modified pig) 
Human 
Bovine 
None 
Arginine 
Lysine 
Tyrosine Histidine 
None 
Arginine (NP-AI) 
Axginine modified 
then reduced (THP-A1) 
Synthetic 
nonapeptide None 
GIP None 
Tryptic digestion 
of GIP None 
50 7/8 
50 0/4 
lOO 0/4 
50 0/8 
50 5/5 
50 7/8 
so 0/8 
50 5/8 
2s 2/16 
50 0/8 
50 0/4 
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by Arg [2]. These three amino acids (Trp, Gln, Lys) 
have been found to occur in the sequence of gastric 
inhibitory polypeptide and in one fragment of a 
tryptic digest [5]. Neither the intact GIP nor the 
fragments obtained by tryptic digestion were found 
to be encephalitogenic in the guinea pig (table 1). 
From this we concluded that the positioning of the 
three 'essential' amino acids in the nonapeptide from 
bovine basic protein may be necessary but not the sole 
requirement for encephalitogenic a tivity. This result 
supports those of Hashim and Sharpe [3] who used 
synthetic peptides ubstituted at positions other than 
3, 8 and 9 of the nonapeptide and found a loss of 
encephalitogenic activity. 
The region around tryptophan residue 116 of the 
intact protein is known to be important for the 
encephalitogenic a tivity. Swanborg [ 12] and Chao 
et al. [13] have shown that chemical modification of 
this sole Trp residue results in a loss of encephalitogenic 
activity. Lindl et al. [4] modified tryptophan residue 
116 in a fragment of the basic protein containing 
residues 89-169 and found that some encephalitogenic 
activity remained. 
We have prepared chemical derivatives of the basic 
protein which are not encephalitogenic although the 
tryptophan region of residues 114-122 is unaltered. 
The human basic protein has an arginine residue at 
position 122 of the intact protein while the bovine 
protein has a lysine residue in this position. Chemical 
modification with citraconic anhydride, a reagent 
specific for amino groups (Lys), should not effect the 
encephalitogenic determinant of the human basic 
protein while nitromalonyl dialdehyde, a reagent 
specific for guanidyl groups hould not effect the 
encephalitogenic determinant of the bovine basic 
protein. However, both of these chemical modifica- 
tions resulted in the abolition of encephalitogenic 
activity (table 1). The cause for this loss of activity 
has not been determined but could have resulted 
from a large change in the overall charge of the 
protein resulting in a conformational change. Other 
derivatives of the lysine and arginine residues of the 
protein resulting in changes in charge retain their 
encephalogenicity [12] and reaction of the amino 
groups with imidates which do not result in a change 
of charge also retains activity even though the 
encephalitogenic determinant maybe modified [14]. 
In the case of the arginine modified derivative, we 
showed that the conditions of chemical modifications 
itself did not cause loss of activity since borohydride 
reduction of this derivative resulted in the regenera- 
tion of the positive charge as well as EAE activity, 
although the arginyl residues remained altered as the 
1,4,5,6-tetrahydropyramidyl derivatives. Iodination 
of the basic protein did not effect the tryptophan 
residue in the protein but decreased the EAE activity 
(table 1) although the protein was extensively 
modified. 
Thus extensive chemical modification of the basic 
protein in regions outside of the encephalitogenic 
determinant does not guarantee the destruction of 
EAE activity but at the same time, the presence of the 
unaltered encephalitogenic determinant (residues 
114-122) is not a sufficient condition for the 
presence of EAE activity as is shown by the inactive 
NP-A1 and citraconylated basic proteins. 
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